Stoquity Living researchResearch LedgerSlicesMethodologyFor institutionsAbout
Stoquity Research Ledger

Illumina (ILMN)

NASDAQ: ILMN · Diagnostics & Research · San Diego, CA

Our rating: Neutral

Neutral reaffirmed at $226.58, moderate conviction, November 2, 2026.

Breaks if: The call turns Positive if revenue growth returns to +5% or above for two consecutive quarterly prints within the next 12 months, signaling the genomics cycle has genuinely re-accelerated. It turns Cautious if revenue declines worsen to -5% or more year-over-year for two consecutive quarters, or if FCF margin slides below 15% in any single quarter.

Key figures

Market value$29.2B
Revenue, last 12 months$4.5B
Net income, last 12 months$895M
Free cash flow, last 12 months$1.1B
Price to earnings32.6×
Free cash flow yield3.6%
Dividend yield0.0%
Operating margin21.2%
Return on equity32.4%
Beta to the S&P 5001.10
Volatility, annualized47.6%

Reported quarters

Quarter endingRevenueYear on yearEarnings per shareFree cash flow
September 27, 2026$1.1B4.2%$1.43$379M
June 28, 2026$1.2B9.4%$1.35$161M
March 29, 2026$1.1B4.8%$0.87$251M
December 28, 2025$1.2B5.0%$2.16$266M
September 28, 2025$1.1B0.4%$0.98$253M
June 29, 2025$1.1B−4.8%$1.49$204M
March 30, 2025$1.0B−3.3%$0.82$208M
December 29, 2024$1.1B−1.6%$1.17$335M

Three-model forecasts for the next quarter

Written November 21, 2026, before the report. Each settles from the SEC filing.

22 ledger entries and 48 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.